Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 06-Mar-24 4:05 PM View:  | Adawi Kamal CFO and Corporate Secretary | Exagen Inc. (XGN) | 04-Mar-24 | Sale | 12,784 | $1.91 | $24,406.90 | (5%) 256.53K to 243.75K | |
| 04-Mar-24 4:08 PM View: | Aballi John President and CEO Director | Exagen Inc. (XGN) | 29-Feb-24 | Grant | 9,804 | $1.91 | $18,725.60 | 2% 590.98K to 600.79K | |
| 22-Feb-24 4:11 PM View: | Adawi Kamal CFO and Corporate Secretary | Exagen Inc. (XGN) | 20-Feb-24 | Grant | 75,000 | -- | -- | 41% 181.53K to 256.53K | |
| 22-Feb-24 4:09 PM View: | Aballi John President and CEO Director | Exagen Inc. (XGN) | 20-Feb-24 | Grant | 175,000 | -- | -- | 42% 415.98K to 590.98K | |
| 08-Feb-24 4:05 PM View: | Adawi Kamal CFO and Corporate Secretary | Exagen Inc. (XGN) | 06-Feb-24 | Sale | 6,738 | $1.95 | $13,133.00 | (4%) 188.27K to 181.53K | |
| 18-Oct-23 4:05 PM View: | Aballi John President and CEO Director | Exagen Inc. (XGN) | 17-Oct-23 | Sale | 33,819 | $1.75 | $59,017.50 | (8%) 449.8K to 415.98K | |
| 06-Sep-23 5:05 PM View: | Aballi John President and CEO Director | Exagen Inc. (XGN) | 31-Aug-23 | Grant | 9,803 | $2.14 | $20,998.00 | 2% 440.0K to 449.8K | |
| 03-Mar-23 4:38 PM View: | Adawi Kamal CFO and Corporate Secretary | Exagen Inc. (XGN) | 02-Mar-23 | Sale | 3,667 | $2.30 | $8,431.53 | (2%) 191.94K to 188.27K | |
| 03-Mar-23 4:37 PM View: | Hazeltine Mark Chief Business Officer | Exagen Inc. (XGN) | 02-Mar-23 | Sale | 3,667 | -- | -- | (2%) 193.87K to 190.21K | |
| 01-Mar-23 4:06 PM View: | Hazeltine Mark Chief Business Officer | Exagen Inc. (XGN) | 27-Feb-23 | Grant | 100,000 | -- | -- | 107% 93.87K to 193.87K | |
| 01-Mar-23 4:06 PM View: | Adawi Kamal CFO and Corporate Secretary | Exagen Inc. (XGN) | 27-Feb-23 | Grant | 100,000 | -- | -- | 109% 91.94K to 191.94K | |
| 10-Feb-23 4:05 PM View: | Adawi Kamal CFO and Corporate Secretary | Exagen Inc. (XGN) | 08-Feb-23 | Sale | 5,821 | $2.69 | $15,670.70 | (6%) 97.76K to 91.94K | |
| 10-Feb-23 4:08 PM View: | Hazeltine Mark Chief Business Officer | Exagen Inc. (XGN) | 08-Feb-23 | Sale | 5,821 | $2.69 | $15,672.50 | (6%) 99.69K to 93.87K | |
| 09-Dec-22 9:00 AM View: | Aballi John President and CEO Director | Exagen Inc. (XGN) | 08-Dec-22 | Private Purchase | 90,000 | $2.68 | $241,200.00 | 26% 350.0K to 440.0K | |
| 18-Oct-22 8:38 PM View: | Aballi John President and CEO Director | Exagen Inc. (XGN) | 16-Oct-22 | Grant | 350,000 | -- | -- | 100% 0 to 350.0K | |
| 02-Mar-22 4:37 PM View: | Rocca Fortunato R. President and CEO Director | Exagen Inc. (XGN) | 01-Mar-22 | Payment of Exercise | 4,322 | $7.12 | $30,772.60 | (3%) 125.0K to 120.68K | |
| 02-Mar-22 4:41 PM View: | Zack Debra Chief Medical Officer | Exagen Inc. (XGN) | 01-Mar-22 | Payment of Exercise | 3,241 | $7.12 | $23,075.90 | (4%) 87.5K to 84.26K | |
| 02-Mar-22 4:40 PM View: | Hazeltine Mark Chief Operating Officer | Exagen Inc. (XGN) | 01-Mar-22 | Payment of Exercise | 3,241 | $7.12 | $23,075.90 | (3%) 102.93K to 99.69K | |
| 02-Mar-22 10:00 PM View: | Adawi Kamal CFO and Corporate Secretary | Exagen Inc. (XGN) | 01-Mar-22 | Payment of Exercise | 3,241 | $7.12 | $23,075.90 | (3%) 101.0K to 97.76K | |
| 08-Feb-22 4:19 PM View: | Rocca Fortunato R. President and CEO Director | Exagen Inc. (XGN) | 04-Feb-22 | Grant | 75,000 | -- | -- | 150% 50.0K to 125.0K | |
| 08-Feb-22 4:23 PM View: | Zack Debra Chief Medical Officer | Exagen Inc. (XGN) | 04-Feb-22 | Grant | 50,000 | -- | -- | 133% 37.5K to 87.5K | |
| 08-Feb-22 4:21 PM View: | Hazeltine Mark Chief Operating Officer | Exagen Inc. (XGN) | 04-Feb-22 | Grant | 63,500 | -- | -- | 161% 39.43K to 102.93K | |
| 08-Feb-22 4:20 PM View: | Adawi Kamal CFO and Corporate Secretary | Exagen Inc. (XGN) | 04-Feb-22 | Grant | 63,500 | -- | -- | 169% 37.5K to 101.0K | |
| 07-Sep-21 8:25 AM View: | Johnson Wendy S. Director | Exagen Inc. (XGN) | 03-Sep-21 | Market Purchase | 1,000 | $14.02 | $14,020.00 | 100% 0 to 1.0K | (2%) |
| 04-Aug-21 6:29 PM View: | Tullis James L L Director | Exagen Inc. (XGN) | 04-Aug-21 | Market Sale (Planned) | 2,100 | $11.39 | $23,917.10 | (< 1%) 1.55M to 1.55M | (3%) |
| 04-Aug-21 6:29 PM View: | Tullis James L L Director | Exagen Inc. (XGN) | 03-Aug-21 | Market Sale (Planned) | 4,300 | $11.77 | $50,617.90 | (< 1%) 1.56M to 1.55M | < 1% |
| 04-Aug-21 6:29 PM View: | Tullis James L L Director | Exagen Inc. (XGN) | 02-Aug-21 | Market Sale (Planned) | 1,800 | $11.92 | $21,454.40 | (< 1%) 1.56M to 1.56M | 1% |
| 29-Jun-21 5:10 PM View: | Tullis James L L Director | Exagen Inc. (XGN) | 29-Jun-21 | Market Sale (Planned) | 5,379 | $14.67 | $78,910.50 | (< 1%) 1.56M to 1.56M | (1%) |
| 29-Jun-21 5:10 PM View: | Tullis James L L Director | Exagen Inc. (XGN) | 28-Jun-21 | Market Sale (Planned) | 10,858 | $14.98 | $162,696.00 | (< 1%) 1.57M to 1.56M | < 1% |
| 29-Jun-21 5:10 PM View: | Tullis James L L Director | Exagen Inc. (XGN) | 25-Jun-21 | Market Sale (Planned) | 8,763 | $16.03 | $140,503.00 | (< 1%) 1.58M to 1.57M | 7% |
| 17-May-21 8:06 PM View: | Hazeltine Mark Chief Operating Officer | Exagen Inc. (XGN) | 17-May-21 | Option Exercise | 1,934 | $0.26 | $502.84 | 5% 37.5K to 39.43K | |
| 25-Feb-21 5:04 PM View: | Rocca Fortunato R. President and CEO Director | Exagen Inc. (XGN) | 23-Feb-21 | Grant | 50,000 | -- | -- | 100% 0 to 50.0K | |
| 25-Feb-21 5:05 PM View: | Adawi Kamal Chief Financial Officer | Exagen Inc. (XGN) | 23-Feb-21 | Grant | 37,500 | -- | -- | 100% 0 to 37.5K | |
| 25-Feb-21 5:05 PM View: | Zack Debra Chief Medical Officer | Exagen Inc. (XGN) | 23-Feb-21 | Grant | 37,500 | -- | -- | 100% 0 to 37.5K | |
| 08-Feb-21 9:44 PM View: | Tullis James L L Director 10% Owner | Exagen Inc. (XGN) | 05-Feb-21 | Market Sale (Planned) | 3,000 | $17.00 | $51,000.00 | (< 1%) 1.59M to 1.58M | (9%) |
| 26-Jan-21 6:30 PM View: | Hunt Holdings Limited Partn... 10% Owner | Exagen Inc. (XGN) | 25-Jan-21 | Market Sale | 28,021 | $16.01 | $448,616.00 | (2%) 1.29M to 1.26M | < 1% |
| 26-Jan-21 6:30 PM View: | Hunt Holdings Limited Partn... 10% Owner | Exagen Inc. (XGN) | 22-Jan-21 | Market Sale | 23,646 | $16.07 | $379,991.00 | (2%) 1.31M to 1.29M | < 1% |
| 21-Jan-21 4:54 PM View: | Hunt Holdings Limited Partn... 10% Owner | Exagen Inc. (XGN) | 21-Jan-21 | Market Sale | 50,000 | $16.01 | $800,700.00 | (4%) 1.36M to 1.31M | (2%) |
| 21-Jan-21 4:54 PM View: | Hunt Holdings Limited Partn... 10% Owner | Exagen Inc. (XGN) | 20-Jan-21 | Market Sale | 30,000 | $16.13 | $483,990.00 | (2%) 1.39M to 1.36M | (2%) |
| 20-Jan-21 5:07 PM View: | Tullis James L L Director 10% Owner | Exagen Inc. (XGN) | 19-Jan-21 | Market Sale (Planned) | 257 | $15.56 | $3,998.46 | (< 1%) 1.59M to 1.59M | (3%) |
| 21-Jan-21 4:54 PM View: | Hunt Holdings Limited Partn... 10% Owner | Exagen Inc. (XGN) | 19-Jan-21 | Market Sale | 30,000 | $16.00 | $480,048.00 | (2%) 1.42M to 1.39M | (3%) |
| 20-Jan-21 5:07 PM View: | Tullis James L L Director 10% Owner | Exagen Inc. (XGN) | 15-Jan-21 | Market Sale (Planned) | 1,014 | $15.51 | $15,725.00 | (< 1%) 1.59M to 1.59M | (3%) |
| 15-Jan-21 5:28 PM View: | Tullis James L L Director 10% Owner | Exagen Inc. (XGN) | 13-Jan-21 | Market Sale (Planned) | 5,729 | $15.63 | $89,534.50 | (< 1%) 1.59M to 1.59M | 6% |
| 14-Jan-21 7:34 PM View: | Hunt Holdings Limited Partn... 10% Owner | Exagen Inc. (XGN) | 12-Jan-21 | Market Sale | 15,000 | $16.04 | $240,584.00 | (1%) 1.44M to 1.42M | 10% |
| 11-Jan-21 9:50 PM View: | Hunt Holdings Limited Partn... 10% Owner | Exagen Inc. (XGN) | 11-Jan-21 | Sale | 7,394 | $16.03 | $118,526.00 | (< 1%) 1.45M to 1.44M | |
| 11-Jan-21 9:50 PM View: | Hunt Holdings Limited Partn... 10% Owner | Exagen Inc. (XGN) | 08-Jan-21 | Sale | 15,186 | $16.07 | $244,039.00 | (1%) 1.46M to 1.45M | |
| 11-Jan-21 9:50 PM View: | Hunt Holdings Limited Partn... 10% Owner | Exagen Inc. (XGN) | 07-Jan-21 | Sale | 10,000 | $16.04 | $160,400.00 | (< 1%) 1.47M to 1.46M | |
| 15-Dec-20 5:20 PM View: | Tullis James L L Director 10% Owner | Exagen Inc. (XGN) | 15-Dec-20 | Sale | 12,000 | $12.23 | $146,726.00 | (< 1%) 1.6M to 1.59M | |
| 16-Dec-20 4:35 PM View: | Nmsic Co-Investment Fund, L... 10% Owner | Exagen Inc. (XGN) | 15-Dec-20 | Sale | 125,000 | $12.00 | $1,500,560.00 | (5%) 2.43M to 2.31M | |
| 14-Dec-20 5:05 PM View: | Tullis James L L Director 10% Owner | Exagen Inc. (XGN) | 11-Dec-20 | Sale | 7,500 | $13.04 | $97,774.50 | (< 1%) 1.61M to 1.6M |
